Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells

G. Sica, G. Lama, F. Iacopino, C. Angelucci, G. Robustelli Della Cuna, P. Marchetti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The effect of Lonidamine (LND) alone or combined with the antiestrogen Tamoxifen (TAM) or Medroxyprogesterone acetate (MPA) on cell proliferation and steroid hormone receptor content of a human estrogen sensitive breast cancer cell line was investigated. LND has a direct growth inhibitory action, even if used at relatively low concentrations (10-7M), and shows the maximum effect at 10-4M. The combination of LND with the antiestrogen does not produce a potentiation of the TAM-induced reduction of cell number, while the association of the drug with MPA seems more effective with respect to MPA alone, at least at certain concentrations. The negative interference observed between LND and TAM may be due to the LND-induced decrease of estrogen receptor levels.

Original languageEnglish
Pages (from-to)2099-2102
Number of pages4
JournalAnticancer Research
Volume11
Issue number6
Publication statusPublished - 1991

Fingerprint

Medroxyprogesterone Acetate
Tamoxifen
Breast Neoplasms
Estrogen Receptor Modulators
Steroid Receptors
Estrogen Receptors
Estrogens
Cell Count
Cell Proliferation
lonidamine
Hormones
Cell Line
Growth
Pharmaceutical Preparations

Keywords

  • Acetate
  • Breast cancer cells
  • Lonidamine
  • Medroxyprogesterone
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sica, G., Lama, G., Iacopino, F., Angelucci, C., Robustelli Della Cuna, G., & Marchetti, P. (1991). Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells. Anticancer Research, 11(6), 2099-2102.

Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells. / Sica, G.; Lama, G.; Iacopino, F.; Angelucci, C.; Robustelli Della Cuna, G.; Marchetti, P.

In: Anticancer Research, Vol. 11, No. 6, 1991, p. 2099-2102.

Research output: Contribution to journalArticle

Sica, G, Lama, G, Iacopino, F, Angelucci, C, Robustelli Della Cuna, G & Marchetti, P 1991, 'Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells', Anticancer Research, vol. 11, no. 6, pp. 2099-2102.
Sica G, Lama G, Iacopino F, Angelucci C, Robustelli Della Cuna G, Marchetti P. Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells. Anticancer Research. 1991;11(6):2099-2102.
Sica, G. ; Lama, G. ; Iacopino, F. ; Angelucci, C. ; Robustelli Della Cuna, G. ; Marchetti, P. / Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells. In: Anticancer Research. 1991 ; Vol. 11, No. 6. pp. 2099-2102.
@article{2d039d95cd0a43daa5de5e172fb379d3,
title = "Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells",
abstract = "The effect of Lonidamine (LND) alone or combined with the antiestrogen Tamoxifen (TAM) or Medroxyprogesterone acetate (MPA) on cell proliferation and steroid hormone receptor content of a human estrogen sensitive breast cancer cell line was investigated. LND has a direct growth inhibitory action, even if used at relatively low concentrations (10-7M), and shows the maximum effect at 10-4M. The combination of LND with the antiestrogen does not produce a potentiation of the TAM-induced reduction of cell number, while the association of the drug with MPA seems more effective with respect to MPA alone, at least at certain concentrations. The negative interference observed between LND and TAM may be due to the LND-induced decrease of estrogen receptor levels.",
keywords = "Acetate, Breast cancer cells, Lonidamine, Medroxyprogesterone, Tamoxifen",
author = "G. Sica and G. Lama and F. Iacopino and C. Angelucci and {Robustelli Della Cuna}, G. and P. Marchetti",
year = "1991",
language = "English",
volume = "11",
pages = "2099--2102",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells

AU - Sica, G.

AU - Lama, G.

AU - Iacopino, F.

AU - Angelucci, C.

AU - Robustelli Della Cuna, G.

AU - Marchetti, P.

PY - 1991

Y1 - 1991

N2 - The effect of Lonidamine (LND) alone or combined with the antiestrogen Tamoxifen (TAM) or Medroxyprogesterone acetate (MPA) on cell proliferation and steroid hormone receptor content of a human estrogen sensitive breast cancer cell line was investigated. LND has a direct growth inhibitory action, even if used at relatively low concentrations (10-7M), and shows the maximum effect at 10-4M. The combination of LND with the antiestrogen does not produce a potentiation of the TAM-induced reduction of cell number, while the association of the drug with MPA seems more effective with respect to MPA alone, at least at certain concentrations. The negative interference observed between LND and TAM may be due to the LND-induced decrease of estrogen receptor levels.

AB - The effect of Lonidamine (LND) alone or combined with the antiestrogen Tamoxifen (TAM) or Medroxyprogesterone acetate (MPA) on cell proliferation and steroid hormone receptor content of a human estrogen sensitive breast cancer cell line was investigated. LND has a direct growth inhibitory action, even if used at relatively low concentrations (10-7M), and shows the maximum effect at 10-4M. The combination of LND with the antiestrogen does not produce a potentiation of the TAM-induced reduction of cell number, while the association of the drug with MPA seems more effective with respect to MPA alone, at least at certain concentrations. The negative interference observed between LND and TAM may be due to the LND-induced decrease of estrogen receptor levels.

KW - Acetate

KW - Breast cancer cells

KW - Lonidamine

KW - Medroxyprogesterone

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0026348258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026348258&partnerID=8YFLogxK

M3 - Article

C2 - 1776846

AN - SCOPUS:0026348258

VL - 11

SP - 2099

EP - 2102

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -